Global Cancer Observatory: Cancer Today. IARC: lung fact sheet; 2020. https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed 20 June 2023.

Cancer.net. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell. Accessed 20 Mar 2023.

National Cancer Institute/Surveillance, Epidemiology, and End Results Program. SEER 22. Adenocarcinoma of the Lung and Bronchus. Stage distribution of SEER incidence cases, 2011–2020. By sexes, all races/ethnicities, all ages. https://seer.cancer.gov/statfacts/html/lungb.html. Accessed 22 June 2023.

Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–40. https://doi.org/10.1016/j.mayocp.2019.01.013.

Article  CAS  PubMed  Google Scholar 

Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865–72. https://doi.org/10.1200/JCO.2004.12.149.

Article  PubMed  Google Scholar 

Waqar SN, Samson PP, Robinson CG, et al. Non-small-cell lung cancer with brain metastasis at presentation. Clin Lung Cancer. 2018;19(4):e373–9. https://doi.org/10.1016/j.cllc.2018.01.007.

Article  PubMed  PubMed Central  Google Scholar 

Lim JH, Um S-W. The risk factors for brain metastases in patients with non-small cell lung cancer. Ann Transl Med. 2018;6(Suppl 1):S66. https://doi.org/10.21037/atm.2018.10.27.

Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322(8):764–74. https://doi.org/10.1001/jama.2019.11058.

Article  CAS  PubMed  Google Scholar 

Wu J, Liu Z, Huang T, Wang Y, et al. Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC. Mol Oncol. 2023;17(5):810–24.

Article  CAS  PubMed  Google Scholar 

Ali S, Górska Z, Duchnowska R, Jassem J. Molecular profiles of brain metastases: a focus on heterogeneity. Cancers (Basel). 2021;13(11):2645.

Article  CAS  PubMed  Google Scholar 

Kim M, Kizilbash SH, Laramy JK, et al. Barriers to effective drug treatment for brain metastases: a multifactorial problem in the delivery of precision medicine. Pharm Res. 2018;35(9):177. https://doi.org/10.1007/s11095-018-2455-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rudmann DG. On-target and off-target-based toxicologic effects. Toxicol Pathol. 2013;41:310–4. https://doi.org/10.1177/0192623312464311.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;372:n71. https://doi.org/10.1136/bmj.n71.

Article  Google Scholar 

Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.1 (updated September 2020). Cochrane, 2020. http://www.training.cochrane.org/handbook. Accessed 14 Aug 2023.

Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898.

Article  PubMed  Google Scholar 

Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 12 Jan 2021.

Addeo A, Hochmair M, Janzic U, et al. Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT). Ther Adv Med Oncol. 2021;13:17588359211059874. https://doi.org/10.1177/17588359211059874.

Article  PubMed  PubMed Central  Google Scholar 

Bai H, Xiong L, Han B. The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer. Onco Targets Ther. 2017;10:2335–40. https://doi.org/10.2147/OTT.S129809.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baldacci S, Besse B, Avrillon V, et al. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: results of the IFCT-1803 LORLATU cohort. Eur J Cancer. 2022;166:51–9. https://doi.org/10.1016/j.ejca.2022.01.018.

Article  CAS  PubMed  Google Scholar 

Bilgin B, Sendur MAN, Yucel S, et al. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in non-small cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021;147(7):2145–52. https://doi.org/10.1007/s00432-020-03501-6.

Article  CAS  PubMed  Google Scholar 

Bozorgmehr F, Kazdal D, Chung I, et al. De novo versus secondary metastatic EGFR-mutated non-small-cell lung cancer. Front Oncol. 2021;11: 640048. https://doi.org/10.3389/fonc.2021.640048.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Camidge D, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. New Engl J Med. 2018;379(21):2027–39. https://doi.org/10.1056/NEJMoa1810171.

Article  CAS  PubMed  Google Scholar 

Chang CY, Chen CY, Chang SC, et al. Efficacy and prognosis of first-line EGFR-tyrosine kinase inhibitor treatment in older adults including poor performance status patients with EGFR-mutated non-small-cell lung cancer. Cancer Manag Res. 2021;13:7187–201. https://doi.org/10.2147/CMAR.S322967.

Article  PubMed  PubMed Central  Google Scholar 

Chen C, Wu Y, Liu BL, et al. Whole-brain radiotherapy can improve the survival of patients with multiple brain metastases from non-small cell lung cancer treated by epidermal growth factor receptor-tyrosine kinase inhibitors. Cancer Manag Res. 2020;12:11333–40. https://doi.org/10.2147/CMAR.S279096.

Article  PubMed  PubMed Central  Google Scholar 

Chen YH, Chen YF, Chen CY, et al. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study. BMC Cancer. 2019;19(1):1006. https://doi.org/10.1186/s12885-019-6140-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen CH, Lee HH, Chuang HY, et al. Combination of whole-brain radiotherapy with epidermal growth factor receptor tyrosine kinase inhibitors improves overall survival in EGFR-mutated non-small cell lung cancer patients with brain metastases. Cancers (Basel). 2019;11(8):1092. https://doi.org/10.3390/cancers11081092.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen H, Wu A, Tao H, et al. Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis: a single institution retrospective analysis. Medicine (Baltimore). 2018;97(44):e13014. https://doi.org/10.1097/MD.0000000000013014.

Article  PubMed  Google Scholar 

Chiu TH, Tung PH, Huang CH, et al. The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis. Sci Rep. 2022;12(1):4398. https://doi.org/10.1038/s41598-022-08449-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Marinis F, Laktionov KK, Poltoratskiy A, et al. Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: interim analysis of a phase 3b study. Lung Cancer. 2021;152:127–34. https://doi.org/10.1016/j.lungcan.2020.12.011.

Article  CAS  PubMed  Google Scholar 

Doherty MK, Korpanty GJ, Tomasini P, et al. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer. Radiother Oncol. 2017;123(2):195–202. https://doi.org/10.1016/j.radonc.2017.03.007.

Article  PubMed  Google Scholar 

Duruisseaux M, Besse B, Cadranel J, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8(13):21903–21917. https://doi.org/10.18632/oncotarget.15746.

El Shafie RA, Seidensaal K, Bozorgmehr F, et al. Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer. ESMO Open. 2021;6(3):100161. https://doi.org/10.1016/j.esmoop.2021.100161.

Article  PubMed  PubMed Central  Google Scholar 

Gijtenbeek RGP, Damhuis RAM, Groen HJM, van der Wekken AJ, van Geffen WH. Nationwide real-world cohort study of first-line tyrosine kinase inhibitor treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer. Clin Lung Cancer. 2020;21(6):e647–53. https://doi.org/10.1016/j.cllc.2020.05.019.

Article  CAS  PubMed  Google Scholar 

He ZY, Li MF, Lin JH, Lin D, Lin RJ. Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study. Cancer Manag Res. 2019;11:2129–38. https://doi.org/10.2147/CMAR.S184922.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horn L, Wang Z, Wu G, et al. Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial. JAMA Oncol. 2021;7(11):1617–25. https://doi.org/10.1001/jamaoncol.2021.3523.

Article  PubMed  Google Scholar 

Huang AC, Huang CH, Ju JS, et al. First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer. Ther Adv Med Oncol. 2021;13:17588359211035710. https://doi.org/10.1177/17588359211035710.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang CH, Ju JS, Chiu TH, et al. Afatinib treatment in a large real-world cohort of non-small cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation. Int J Cancer. 2022;150(4):626–35. https://doi.org/10.1002/ijc.33821.

Article  CAS  PubMed  Google Scholar